newsfilter
← Latest News
GlobeNewswire·

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®**